Prof. Dr. Raja Atreya

Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease (2022) Schneider I, Allner C, Mühl L, Melde M, Lissner D, Mantzivi E, Glauben R, et al. Journal article Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT (ErLangen Endocytoscopy in ColiTis) score (with videos) (2022) Vitali F, Morgenstern N, Eckstein M, Atreya R, Waldner M, Hartmann A, Neurath M, Rath T Journal article Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial (2022) Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, et al. Journal article Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study. (2022) Simon D, Tascilar K, Fagni F, Kleyer A, Krönke G, Meder C, Dietrich P, et al. Journal article CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease (2022) Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, et al. Journal article A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, et al. Conference contribution Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study (2022) Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Deppe H, Mohl W, Teich N, Hoffstadt M, et al. Conference contribution Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy (2022) Baert FJ, Atreya R, Kakuta Y, Long M, Roblin X, Neimark E, Song A, et al. Conference contribution Neutrophils prevent rectal bleeding in Ulcerative Colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis (2022) Leppkes M, Lindemann A, Goesswein S, Paulus S, Roth D, Hartung A, Liebing E, et al. Conference contribution